O	0	1	A
O	2	12	randomised
O	13	18	phase
O	19	21	II
O	22	27	study
O	28	30	of
O	31	34	two
O	35	44	different
O	45	54	schedules
O	55	57	of
B-intervention	58	67	pegylated
I-intervention	68	77	liposomal
I-intervention	78	89	doxorubicin
O	90	92	in
O	93	103	metastatic
O	104	110	breast
O	111	117	cancer
O	118	119	(
O	119	124	EORTC
O	124	125	-
O	125	130	10993
O	130	131	)
O	131	132	.

B-total-participants	133	136	One
I-total-participants	137	144	hundred
I-total-participants	145	148	and
I-total-participants	149	156	sixteen
B-eligibility	157	162	women
I-eligibility	163	167	with
I-eligibility	168	178	measurable
I-eligibility	179	189	metastatic
I-eligibility	190	196	breast
I-eligibility	197	203	cancer
O	204	216	participated
O	217	219	in
O	220	221	a
O	222	232	randomised
O	233	238	phase
O	239	241	II
O	242	247	study
O	248	250	of
O	251	257	single
O	258	263	agent
O	264	273	liposomal
O	274	283	pegylated
O	284	295	doxorubicin
O	296	297	(
O	297	303	Caelyx
O	303	304	)
O	305	310	given
O	311	317	either
O	318	320	as
O	321	322	a
O	323	325	60
O	326	328	mg
O	328	329	/
O	329	331	m2
O	332	337	every
O	338	339	6
O	340	345	weeks
O	346	347	(
O	347	350	ARM
O	351	352	A
O	352	353	)
O	354	356	or
O	357	359	50
O	360	362	mg
O	362	363	/
O	363	365	m2
O	366	371	every
O	372	373	4
O	374	379	weeks
O	380	381	(
B-control	381	384	ARM
I-control	385	386	B
O	386	387	)
O	388	396	schedule
O	396	397	.

O	398	406	Patients
O	407	411	were
B-age	412	416	over
I-age	417	419	65
I-age	420	425	years
O	426	428	of
O	429	432	age
O	433	435	or
O	435	436	,
O	437	439	if
O	440	447	younger
O	447	448	,
O	449	452	had
O	453	460	refused
O	461	463	or
O	464	468	been
O	469	479	unsuitable
O	480	483	for
O	484	492	standard
O	493	507	anthracyclines
O	507	508	.

O	509	512	The
O	513	517	aims
O	518	520	of
O	521	524	the
O	525	530	study
O	531	535	were
O	536	538	to
O	539	547	evaluate
O	548	556	toxicity
O	557	560	and
O	561	565	dose
O	566	574	delivery
O	575	579	with
O	580	583	the
O	584	587	two
O	588	597	schedules
O	598	601	and
O	602	608	obtain
O	609	616	further
O	617	628	information
O	629	631	on
O	632	635	the
O	636	644	response
O	645	649	rate
O	650	652	of
O	653	662	liposomal
O	663	672	pegylated
O	673	684	doxorubicin
O	685	687	as
O	688	689	a
O	690	696	single
O	697	702	agent
O	703	705	in
O	706	719	anthracycline
O	720	723	nai
O	724	726	ve
O	727	735	advanced
O	736	742	breast
O	743	749	cancer
O	749	750	.

O	751	757	Twenty
O	757	758	-
O	758	761	six
O	762	770	patients
O	771	774	had
O	775	783	received
O	784	789	prior
O	790	798	adjuvant
O	799	811	chemotherapy
O	812	813	(
O	813	822	including
O	823	825	an
O	826	839	anthracycline
O	840	842	in
O	843	845	10
O	845	846	)
O	846	847	.

O	848	855	Sixteen
O	856	859	had
O	860	868	received
O	869	872	non
O	872	873	-
O	873	886	anthracycline
O	886	887	-
O	887	892	based
O	893	898	first
O	898	899	-
O	899	903	line
O	904	916	chemotherapy
O	917	920	for
O	921	929	advanced
O	930	937	disease
O	937	938	.

B-total-participants	939	942	One
I-total-participants	943	950	hundred
I-total-participants	951	954	and
I-total-participants	955	961	eleven
O	962	970	patients
O	971	975	were
O	976	985	evaluable
O	986	989	for
O	990	998	toxicity
O	999	1002	and
B-total-participants	1003	1006	106
O	1007	1010	for
O	1011	1019	response
O	1019	1020	.

O	1021	1024	The
O	1025	1034	delivered
O	1035	1039	dose
O	1040	1049	intensity
O	1050	1051	(
O	1051	1053	DI
O	1053	1054	)
O	1055	1058	was
O	1059	1060	9
O	1060	1061	.
O	1061	1062	8
O	1063	1065	mg
O	1065	1066	/
O	1066	1068	m2
O	1069	1070	(
O	1070	1072	95
O	1072	1073	%
O	1074	1076	CI
O	1076	1077	,
O	1078	1079	7
O	1079	1080	.
O	1080	1081	2
O	1081	1082	-
O	1082	1084	10
O	1084	1085	.
O	1085	1086	4
O	1086	1087	)
O	1088	1092	with
B-iv-bin-abs	1093	1095	37
O	1096	1097	(
B-iv-bin-percent	1097	1099	69
I-iv-bin-percent	1099	1100	%
O	1100	1101	)
B-outcome	1102	1111	achieving
I-outcome	1112	1113	a
I-outcome	1114	1116	DI
I-outcome	1117	1119	of
I-outcome	1120	1121	>
I-outcome	1121	1123	90
I-outcome	1123	1124	%
O	1125	1127	on
O	1128	1131	ARM
O	1132	1133	A
O	1134	1137	and
O	1138	1140	11
O	1140	1141	.
O	1141	1142	9
O	1143	1145	mg
O	1145	1146	/
O	1146	1148	m2
O	1149	1150	(
O	1150	1152	95
O	1152	1153	%
O	1154	1156	CI
O	1156	1157	,
O	1158	1159	7
O	1159	1160	.
O	1160	1161	5
O	1161	1162	-
O	1162	1164	12
O	1164	1165	.
O	1165	1166	8
O	1166	1167	)
O	1168	1172	with
B-cv-bin-abs	1173	1175	37
O	1176	1177	(
B-cv-bin-percent	1177	1179	65
I-cv-bin-percent	1179	1180	%
O	1180	1181	)
O	1182	1191	achieving
O	1192	1193	a
O	1194	1196	DI
O	1197	1199	of
O	1200	1201	>
O	1201	1203	90
O	1203	1204	%
O	1205	1207	on
O	1208	1211	ARM
O	1212	1213	B
O	1213	1214	.

O	1215	1218	The
B-outcome	1219	1226	adverse
I-outcome	1227	1232	event
O	1233	1241	profiles
O	1242	1244	of
O	1245	1248	the
O	1249	1252	two
O	1253	1262	schedules
O	1263	1267	were
O	1268	1278	distinctly
O	1279	1288	different
O	1288	1289	.

B-outcome	1290	1299	Mucositis
O	1300	1303	was
O	1304	1308	more
O	1309	1315	common
O	1316	1320	with
O	1321	1324	the
O	1325	1330	every
O	1331	1332	6
O	1333	1338	weeks
O	1339	1346	regimen
O	1347	1348	(
B-iv-bin-percent	1348	1350	35
I-iv-bin-percent	1350	1351	%
O	1352	1355	CTC
O	1356	1361	grade
O	1362	1363	3
O	1363	1364	/
O	1364	1365	4
O	1366	1368	in
O	1369	1372	ARM
O	1373	1374	A
O	1374	1375	,
B-cv-bin-percent	1376	1378	14
I-cv-bin-percent	1378	1379	%
O	1380	1382	in
O	1383	1386	ARM
O	1387	1388	B
O	1388	1389	)
O	1390	1393	but
B-outcome	1394	1400	palmar
I-outcome	1401	1408	plantar
I-outcome	1409	1427	erythrodysesthesia
I-outcome	1428	1429	(
I-outcome	1429	1432	PPE
I-outcome	1432	1433	)
O	1434	1437	was
O	1438	1442	more
O	1443	1451	frequent
O	1452	1456	with
O	1457	1460	the
O	1461	1466	every
O	1467	1468	4
O	1469	1474	weeks
O	1475	1482	regimen
O	1483	1484	(
B-iv-bin-percent	1484	1485	2
I-iv-bin-percent	1485	1486	%
O	1487	1490	CTC
O	1491	1496	grade
O	1497	1498	3
O	1498	1499	/
O	1499	1500	4
O	1501	1503	in
O	1504	1507	ARM
O	1508	1509	A
O	1509	1510	,
B-cv-bin-percent	1511	1513	16
I-cv-bin-percent	1513	1514	%
O	1515	1517	in
O	1518	1521	ARM
O	1522	1523	B
O	1523	1524	)
O	1524	1525	.

O	1526	1535	Confirmed
B-outcome	1536	1545	objective
I-outcome	1546	1553	partial
I-outcome	1554	1563	responses
O	1564	1566	by
O	1567	1573	RECIST
O	1574	1582	criteria
O	1583	1587	were
O	1588	1592	seen
O	1593	1597	with
O	1598	1602	both
O	1603	1612	schedules
O	1612	1613	;
B-iv-bin-abs	1614	1616	15
O	1616	1617	/
B-intervention-participants	1617	1619	51
O	1620	1621	(
B-iv-bin-percent	1621	1623	29
I-iv-bin-percent	1623	1624	%
O	1624	1625	)
O	1626	1628	on
O	1629	1632	ARM
O	1633	1634	A
O	1635	1638	and
B-cv-bin-abs	1639	1641	17
O	1641	1642	/
B-control-participants	1642	1644	56
O	1645	1646	(
B-cv-bin-percent	1646	1648	31
I-cv-bin-percent	1648	1649	%
O	1649	1650	)
O	1651	1653	on
O	1654	1657	ARM
O	1658	1659	B
O	1659	1660	.

O	1661	1670	Liposomal
O	1671	1680	pegylated
O	1681	1692	doxorubicin
O	1693	1699	showed
O	1700	1711	significant
O	1712	1720	activity
O	1721	1723	in
O	1724	1732	advanced
O	1733	1739	breast
O	1740	1746	cancer
O	1747	1751	with
O	1752	1753	a
O	1754	1763	generally
O	1764	1774	favourable
O	1775	1779	side
O	1779	1780	-
O	1780	1786	effect
O	1787	1794	profile
O	1794	1795	.

O	1796	1799	The
O	1800	1804	high
O	1805	1814	frequency
O	1815	1817	of
O	1818	1828	stomatitis
O	1829	1833	seen
O	1834	1838	with
O	1839	1840	6
O	1841	1847	weekly
O	1848	1857	treatment
O	1858	1863	makes
O	1864	1868	this
O	1869	1872	the
O	1873	1877	less
O	1878	1887	preferred
O	1888	1890	of
O	1891	1894	the
O	1895	1898	two
O	1899	1908	schedules
O	1909	1915	tested
O	1915	1916	.
